In addition to enhancements made every year since recently revised our Political Engagement and Lobbying Policy to clarify the Board’s oversight of lobbying activities and expenditures related to laws or regulations governing the distribution of controlled substances – and to reflect the Board’s commitment to disclose to our shareholders on an annual basis the aggregate dollars we spend on lobbying activities – including our policy priorities, and material lobbying efforts in the year.